

TRANSENERIX INC.

FORM 8-K (Current report filing)

Filed 05/03/17 for the Period Ending 05/03/17

Address	635 DAVIS DRIVE SUITE 300 MORRISVILLE, NC 27560
Telephone	919-765-8400
CIK	0000876378
Symbol	TRXC
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 3, 2017

TransEnterix, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-19437

11-2962080

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

635 Davis Drive, Suite 300, Morrisville, North
Carolina

27560

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

919-765-8400

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

As previously reported on Form 8-K filed with the Securities and Exchange Commission on April 28, 2017, TransEnterix, Inc. (the "Company") entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated on April 28, 2017, relating to an underwritten public offering of an aggregate of 24,900,000 units (the "Units") each consisting of one share of the Company's common stock, par value \$0.001 per share (the "Common Stock"), a Series A warrant to purchase one share of Common Stock, and a Series B warrant to purchase 0.75 shares of Common Stock. The closing of the offering took place on May 3, 2017.

As approved in advance by the Audit Committee in accordance with the Company's corporate governance guidelines, Andrea Biffi a director of the Company, Joseph P. Slattery, Executive Vice President and Chief Financial Officer of the Company, and Aisling Capital III, L.P. a beneficial owner of greater than five percent of the Company's outstanding Common Stock, of which Aftab Kherani, a director of the Company, is a partner, participated in the offering.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

May 3, 2017

TransEnterix, Inc.

By: */s/ Joseph P. Slattery*

Name: Joseph P. Slattery

Title: EVP and CFO